

REVIEW ON ANTIMALARIAL DRUGS

PIYUSH KALIA, MANEESH BANYAL, JYOTI GUPTA

IEC School of Pharmacy, IEC University, Himachal Pradesh, 174103 INDIA

ABSTRACT

The primary reason for the sharp rise in recent years in the search and development of novel antimalarial medications has been drug resistance to those already in use. Data from a variety of preclinical test systems are taken into account when choosing potential medications for human clinical trials and when developing clinical protocols. Every chemical is first evaluated using one or more primary screening models.

A substance that passes the first screening test with well-defined criteria as "active" is evaluated further in a series of subsequent clinical tests. Upon completion of every testing phase, a determination is made regarding whether to proceed with the chemical to the subsequent phase or end it. Primary screening tests ought to be low-cost, require a minimal amount of test substance, have a high degree of repeatability, high throughput, and excellent sensitivity.

More sensitive and affordable screening models are required, as the need for newer and more effective antimalarial medications, particularly in tropical nations, is expanding.

This review provides an update on the many traditional and cutting-edge in vitro and in vivo screening techniques used to assess antimalarial drugs.

Introduction

ONE OF THE OLDEST DISEASES IN WORLD HISTORY IS MALARIA.

During the 18th century, Malaria was linked by the Italians to "bad air," or Mala RIA, which is where the name Malaria originates. IT IS A PROTOZOAL DISEASE TRANSMITTED TO MAN BY CERTAIN SPECIES OF INFECTED FEMALE ANOPHELINE MOSQUITO, CAUSED BY PARASITES OF THE GENUS PLASMODIUM.

ONE OF THE MOST IMPORTANT DISEASES IN THE DEVELOPING

WORLD, malaria continues to kill one to three million people year and infect 300–500 million more.[1] The National Malaria Eradication Programme in India began in 1958 and resulted in the disease's near total eradication in the 1960s. However, it staged a comeback in the 1970s and continues to predominate in endemic or sub-endemic proportions in various regions due to the development of insecticide resistance among mosquitoes and other factors. Malaria clinically presents as fever, chills, dysphagia, and anaemia. DELIRIUM, METABOLIC ACIDOSIS, CEREBRAL MALARIA, MULTI ORGAN SYSTEM FAILURE, COMA, AND DEATH MAY FOLLOW A SERIOUS FORM OF THE DISEASE.

When a mosquito bites a mosquito carrying sporozoites, it produces gametocytes, which are infectious to mosquitoes, and trophozoites, which are blood stage infections. The mosquito absorbs the gametocytes from the human blood, which results in fertilisation and the development of zygotes in the mosquito's midgut. The next step is the creation of haploid sporozoites, which enter the mosquito's salivary glands and are then bitten back into humans.

Utilise antimalarial drugs Antimalarial drugs and personal preventivemeasures are combined to prevent malaria, especially while visiting regions where the disease is endemic. The following are some essential tactics for preventing malaria:

To find out which antimalarial drug is right for you, speak with a doctor or travel medicine specialist well in advance if you're visiting a region where malaria is endemic. Mefloquine, hydroxychloroquine, atovaquone-proguanil, doxycycline, and chloroquine are typical choices. As directed by your doctor, take the medication prior to travel, during your stay in the malaria-endemic area, and for a predetermined amount of time after you return, depending on the prescription.

Prevent Mosquito Bites: Apply insect repellents like DEET (N, N- diethyl-meta-toluamide), picaridin, or IR3535 on exposed skin and clothing to reduce your risk of getting bitten by mosquitoes. When mosquitoes are most active at morning and dusk, wear long sleeves, long pants, socks and closed-toe shoes. For further protection, wear clothes and equipment treated with permethrin. To provide a physical barrier against mosquitoes while you sleep, sleep under bednets coated with pesticides, ideally ones treated with long-lasting insecticides (LLINs).

Eliminate Mosquito Breeding Sites: Since mosquitoes like stagnant water, you may reduce the chance that they will breed close to your home or place of business by taking out, covering, or treating any containers that hold

water (such flower pots, buckets, and tyres). To keep mosquitoes out of houses, make sure screens are placed on windows and doors.

Remain in Air-Conditioned or Screened Accommodations: To reduce mosquitoes entering indoor spaces, select lodgings with air conditioning or screened windows and doors.

Recognise Peak Mosquito Activity: Take additional care to prevent mosquito bites during the hours when mosquitoes are most active, which are usually from twilight to dawn.

Be Wary of Rural Areas: When visiting isolated or rural locations where the danger of malaria may be increased, take extra measures. Compared to urban areas, malaria transmission is frequently more intense. **Seek Medical Attention Right Away if Symptoms Exist:** Recognise the signs and symptoms of malaria, which include fever, chills, headache, sore muscles, and exhaustion. Even if you have been taking antimalarial medicine as a preventive strategy, you should still seek medical assistance right away if you develop symptoms suggestive of malaria during or after your vacation to a malaria-endemic area.

Over the past twenty years, the management of malaria has become more challenging due to the rise in resistance to commonly used antimalarial medications, including chloroquine. The capacity of a parasite strain to grow or survive in the presence of a drug concentration that would normally stop the parasites from multiplying or kill them is known as drug resistance. Newer medications are required to address the issue of resistance. Under fact, there are currently an unparalleled amount of malaria research and development initiatives under progress, encompassing numerous novel pharmacological targets for antimalarial treatment. Safe and effective drug development is the aim. The goal of this article is to give postgraduate and research students practical knowledge about the several *in vitro* and *in vivo* screening techniques that are used or suggested for the development of antimalarial drugs.

In vitro techniques for antimalarial drug screening One essential element of antimalarial medication screening is the use of *in vitro* activity screens. Its foundation is the capacity to grow *Plasmodium falciparum* *in vitro* using human erythrocytes. In addition to medication screening and long-term evaluation, the development of methods for the continuous cultivation of *Plasmodium falciparum* is a dependable source for the continuous stock culture of parasites.

Human erythrocytes incubated at 38°C in RPMI 1640 medium with human serum or albumin (a lipid-rich bovine serum albumin) can now support the continuous cultivation of *Plasmodium falciparum*. The rate at which erythrocytes degrade *in vitro* and the pH drift that occurs when cells are exposed to outside air both seem to be decreased by albumin. The discovery that parasites grew more favourably in a settled layer of red cells with a constant, slow flow of medium over it allowed for continuous cultivation.

Using this technique, a tiny quantity of Aotus monkey blood infected with *falciparum* is added to a solution of human AB group erythrocytes. Because type AB blood can be combined with Aotus blood without running the risk of agglutinating Aotus cells, it is employed. This suspension is put into flow vials that have a 5% O₂ and 7% CO₂ atmosphere and a medium flow rate of 2 ml/hr over the settling cells. As the cultures continue to thrive, fresh human red blood cells are added to them every third or fourth day after the fourth day. [2] It is important to take precautions to prevent parasite cultures from reaching an excessively high parasitemia (i.e., percentage of parasitized erythrocytes) since, depending on the cell line chosen, parasites multiply three to eight times every 48 hours. The parasite's mechanism of entrance into erythrocytes, drug discovery, strain and clone isolation and characterization, identification of immunogenic antigens, and parasite genome analysis are all being studied through *Plasmodium falciparum* culture. It is possible to provide a number of well-characterized strains.

The term "antimalarial drug" refers to pharmaceuticals used to treat or prevent malaria, a potentially fatal parasitic disease spread by mosquito bites. Antimalarial medications come in various forms, each with a unique mode of action, level of efficacy, and set of side effects.

The medications chloroquine and hydroxychloroquine were formerly often used for the treatment as well as the prevention of malaria.

They function by building up in the parasite's acidic feeding vacuoles, where they raise pH and obstruct vital metabolic functions. However, their effectiveness has decreased in many areas due to widespread resistance in the most fatal malaria parasite, *Plasmodium falciparum*. Artemisinin and its byproducts (Artesunate, Artemether): For uncomplicated malaria caused by *Plasmodium falciparum*, artemisinin-based combination therapies (ACTs) are now the most effective treatments available. They cause damage to the parasite's cell membranes, which ultimately results in its demise. Drugs based on artemisinin have a high rate of effectiveness and are quick acting. Concerns exist, though, regarding new resistance.

Mefloquine: This medication works well against a variety of malaria species and is frequently used as a preventative measure in regions where chloroquine-resistant malaria is prevalent. In order to destroy the parasite, mefloquine works by obstructing its ability to metabolise and use haemoglobin. On the other hand, it may result

in neuropsychiatric adverse effects, such as vivid nightmares, sleeplessness, and in rare instances, more severe problems including depression or psychosis.

Atovaquone-Proguanil: This combo medication is used to treat and prevent malaria. Atovaquone disrupts the parasite's electron transport within its mitochondria, whereas proguanil blocks the enzyme that is essential for DNA synthesis. Although gastrointestinal adverse effects such as nausea, vomiting, or diarrhoea are rare, it is often well tolerated.

Doxycycline: mainly used as an antibiotic, doxycycline is also used to control malaria in regions where strains of the disease are resistant to chloroquine. Inhibiting protein synthesis is how it functions.

Primaquine is a medication that is mostly used to treat *P. vivax* and

P. ovale malaria. It functions by obstructing the parasite's hepatic replication, hence averting relapses. On the other hand, it can result in hemolytic anaemia in those who have a shortage of glucose-6-phosphate dehydrogenase (G6PD), a condition that is more prevalent in some ethnic groups.

Quinine and Quinidine: These medications are used for severe malaria patients or when alternative treatments are not accessible. They function by obstructing the parasite's ability to degrade haemoglobin, which causes a buildup and toxicity of the substance. Quinidine can result in cardiac arrhythmias, whereas quinine is linked to adverse effects such as cinchonism (ear ringing, headache, and nausea).

Tafenoquine: This medication is used for radical cure (prevention of relapse) and is comparable to primaquine.

persons lacking in G6PD. It is noteworthy that the selection of an antimalarial medication is contingent upon various aspects, including the malaria parasite species prevalent in the area, drug resistance trends, the medical background of the patient, and any potential contraindications or adverse effects. To choose which antimalarial drug is best for you, always seek advice from a medical expert.

Artemisinin-based Combination Therapy is the antimalarial medication that is most often used worldwide (ACT). The World Health Organisation (WHO) advises using ACTs as the first line of treatment for simple malaria brought on by the most lethal malaria parasite, *Plasmodium falciparum*.

The main ingredients in ACTs are artemisinin, which is extracted from the sweet wormwood plant (*Artemisia annua*) and its derivatives, including artesunate, artemether, and dihydroartemisinin. They cause damage to the parasite's cell membranes, which ultimately results in its demise. Because of their quick action, these medications quickly lower the bloodstream's parasite burden. Combining the artemisinin component with a longer-acting companion medication helps eradicate any residual parasites and lowers the possibility of developing resistance. Lumefantrine, amodiaquine, mefloquine, and piperazine are a few examples of common companion medications. A synergistic effect is produced when artemisinin is used with a companion medication, increasing treatment efficacy and lowering the chance of treatment failure.

ACTs have been shown to be extremely successful in combating multidrug-resistant forms of *Plasmodium falciparum*.

Adverse effects of artemisinin

1. Effects on the Gastrointestines:

Symptoms include nausea, vomiting, diarrhoea, and stomach discomfort are the most often reported adverse effects.

Usually, these symptoms are minor and fleeting. **Neurological Effects:** When taking artemisinin on their own, some people may develop weakness, headaches, or dizziness.

2. Allergic Reactions:

Although uncommon, allergic reactions to derivatives of artemisinin can happen. An allergic reaction might cause a rash, itching, swelling in the face or throat, and breathing difficulties. Immediately seek medical assistance if symptoms suggest an allergic reaction. Rarely, artemisinin derivatives may result in liver toxicity, which is indicated by high blood liver enzyme levels. Abdominal pain, dark urine, and jaundice—a yellowing of the skin and eyes—are possible signs of liver damage. Liver function ought to.

3. Haematological Effects: Derivatives of artemisinin may momentarily reduce haemoglobin levels, platelet counts,

and white blood cell counts. These side effects, however, normally disappear during the course of treatment and are not clinically noteworthy. **QT Prolongation:** Rare reports of artemisinin derivatives resulting in an extended

QT interval on an electrocardiogram (ECG) have been made. Serious cardiac arrhythmias may result from this, however they are incredibly uncommon. It's crucial to remember that major adverse effects are uncommon with artemisinin-based combination treatments (ACTs), which are normally used for brief courses of treatment (generally three days) to treat malaria.

Nonetheless, people who already have a medical history, such as liver illness or heart irregularities, should use artemisinin-based medications cautiously and under constant supervision from a physician. As usual, any odd or worrisome symptoms while taking medications based on artemisinin should be.

Benefits of artemisinin: Drugs containing artemisinin are known for their rapid onset of action. They are incredibly effective at quickly reducing the parasite load in the bloodstream in comparison to other antimalarial drugs, which leads to a quicker resolution of symptoms and a quicker recovery. **High Performance:** Artemisinin-based combination treatments (ACTs) are the most successful treatment for uncomplicated malaria, which is caused by *Plasmodium falciparum*, the malaria parasite that is most deadly. When artemisinin is administered in conjunction with a partner, a synergistic effect results.

